文献速递银屑病与炎症性皮肤病

比美吉珠单抗治疗中重度斑块状银屑病2年安全性和疗效:BE SURE随机对照试验及BE BRIGHT开放标签扩展的长期结果

Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
PubMed 文献 · Br J Dermatol · 2023-01-01

BE SURE为期56周的双盲III期随机对照试验将中重度斑块状银屑病患者按1:1:1随机分配至比美吉珠单抗320mg每4周组、比美吉珠单抗320mg每4周至第16周后改为每8周组或阿达木单抗40mg每2周至第24周后换用比美吉珠单抗320mg每4周组,随后可进入BE BRIGHT开放标签扩展。至第104周,比美吉珠单抗各组PASI 90和PASI 100应答率与第16周相当,阿达木单抗换药后应答率迅速大幅提升,安全性与已知一致,无新安全信号。

要点

  • 至第104周,比美吉珠单抗Q4W组PASI 90为91.2%、PASI 100为72.3%,Q4W/Q8W组分别为89.7%和68.1%。
  • 阿达木单抗组第24周换用比美吉珠单抗后应答迅速提升,第104周PASI 90达96.9%、PASI 100达70.2%。
  • 比美吉珠单抗治疗组最常见TEAE为鼻咽炎、口腔念珠菌病和上呼吸道感染,严重TEAE发生率低。

核心结论

  • 比美吉珠单抗随机组至第16周观察到的临床应答持续至治疗104周,无论Q4W或Q8W维持给药。
  • 第24周从阿达木单抗换用比美吉珠单抗的患者应答率也持续至第104周,且与比美吉珠单抗组相似。
  • 比美吉珠单抗耐受性良好,无新安全信号。

研究设计与样本

  • BE SURE为56周双盲III期随机对照试验,患者按1:1:1随机分配至比美吉珠单抗320mg Q4W组、比美吉珠单抗320mg Q4W至第16周后Q8W组或阿达木单抗40mg每2周至第24周后换用比美吉珠单抗320mg Q4W组。
  • 完成BE SURE后可进入正在进行的BE BRIGHT开放标签扩展,可根据银屑病面积和严重程度指数(PASI)调整剂量。
  • BE BRIGHT主要结局为治疗中出现的不良事件(TEAE)发生率,安全性数据按研究期报告至第104周。
  • 疗效数据按初始随机分组对意向治疗人群报告至第104周,关键结局为PASI较基线改善≥90%(PASI 90)和100%改善(PASI 100)。

主要发现

  • 随机至比美吉珠单抗的患者中,158例分配至Q4W组,161例分配至Q4W/Q8W组。
  • 第104周,Q4W组和Q4W/Q8W组分别有91.2%和89.7%的患者达到PASI 90,分别有72.3%和68.1%达到PASI 100,与第16周结果相当。
  • 随机至阿达木单抗的159例患者中,第24周换用比美吉珠单抗后应答迅速且大幅增加;第104周分别有96.9%和70.2%的患者达到PASI 90和PASI 100。
  • 第24至104周,任何比美吉珠单抗治疗组中最常见的三种TEAE为鼻咽炎、口腔念珠菌病和上呼吸道感染。
  • 严重TEAE发生率低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab with no unexpected safety findings. OBJECTIVES: To provide efficacy and safety data over 2 years of bimekizumab treatment compared with adalimumab from BE SURE and the BE BRIGHT open-label extension (OLE) in patients with moderate-to-severe plaque psoriasis. METHODS: The 56-week double-blinded BE SURE phase III randomized controlled trial randomized patients 1 : 1 : 1 to bimekizumab 320 mg every 4 weeks (Q4W), bimekizumab 320 mg Q4W to week 16 then every 8 weeks (Q8W), or adalimumab 40 mg every 2 weeks to week 24 then bimekizumab 320 mg Q4W. After completing BE SURE, patients could enter the ongoing BE BRIGHT OLE, with possible dosing adjustments based on Psoriasis Area and Severity Index (PASI). The primary outcome in BE BRIGHT was incidence of treatment-emergent adverse events (TEAEs); safety data are reported by study period through week 104. Efficacy data are reported for the intention-to-treat population through week 104 by initial randomization group, with ≥ 90% improvement from baseline PASI (PASI 90) and 100% improvement (PASI 100) as key outcomes. RESULTS: Of the patients randomized to bimekizumab, 158 were assigned to Q4W, and 161 to Q4W/Q8W. At week 104, PASI 90 was achieved by 91.2% and 89.7%, and PASI 100 was achieved by 72.3% and 68.1%, for Q4W and Q4W/Q8W, respectively; comparable to week 16 results. Among the 159 patients randomized to adalimumab, responses rapidly and substantially increased after the week 24 bimekizumab switch; at week 104, 96.9% and 70.2% of patients achieved PASI 90 and PASI 100 respectively. Through weeks 24-104, the three most common TEAEs in any bimekizumab-treated group were nasopharyngitis, oral candidiasis and upper respiratory tract infection. Rates of serious TEAEs were low. CONCLUSIONS: Clinical responses observed through week 16 of BE SURE in patients randomized to bimekizumab were sustained through 104 weeks of treatment, regardless of Q4W or Q8W maintenance dosing. Response rates were also sustained through week 104 in patients who switched from adalimumab to bimekizumab at week 24, and were similar to those observed in the bimekizumab groups. Bimekizumab was well tolerated with no new safety signals.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Thaçi D, Vender R, de Rie MA, et al. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023. PMID: 36689515. doi:10.1093/bjd/ljac021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。